HBM Healthcare Investments AG
Horizon Therapeutics to acquire HBM portfolio company Viela Bio for USD 3.05 billion in cash
HBM Healthcare Investments AG / Key word(s): Acquisition Horizon Therapeutics (Nasdaq: HZNP) and Viela Bio (Nasdaq: VIE) today announced that the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio for USD 53.00 per share in cash, which represents a fully diluted equity value of approximately USD 3.05 billion. The deal is expected to close by the end of the first quarter 2021. End of ad hoc announcement
|